Company intelligence / Profile preview
Santen Pharmaceutical
Osaka, Osaka, Japansanten.com ↗
- Ownership
- Public · 4536
- Employees
- ~4000
- Development stage
- Other
01
Overview
Santen Pharmaceutical is a global leader in ophthalmology, with a broad commercial portfolio and over 20 pipeline products advancing through various clinical stages, targeting indications like glaucoma, dry eye, and ocular infections. Its marketed portfolio includes drugs for glaucoma (such as tapros, cosopt, eybelis), dry eye (hyalein, ikervis), anti-infective, and anti-inflammatory therapies, with continued investment in novel ophthalmic drug delivery platforms and emerging candidates for additional ocular disorders[3][4][6].
- Therapeutic areas
- ImmunologyInfectious DiseasesOphthalmology
- Modalities
- Small moleculeBiologicDevice
- Industry
- Biotech
02
Drug pipeline
43 assets42 more assets in the full pipeline.
03
Partnerships
Ocular Therapeutix
04
Financials
- Market cap
- $3.8B
- Total revenue
- $1.8B
- Enterprise value
- $3.5B
Beyond the preview
Go deeper on Santen Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Santen Pharmaceutical.